X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

"If Washington isn’t careful, we might leave innovation behind"

By Robert Zirkelbach  |    June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate...   Read More

New report finds 15 new oncology therapies launched last year

By Holly Campbell  |    June 5, 2019
A record 15 new oncology therapeutics launched in 2018 for 17 tumor types, according to IQVIA’s “Global Oncology Trends 2019” report. This progress includes a continued shift toward precision...   Read More

Guest Post: Using the patient voice to go boldly

By Guest Contributor  |    May 30, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New Report: Advanced manufacturing powering innovative biopharmaceuticals

By Tim McClung  |    May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...   Read More

IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry

By Tom Wilbur  |    May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...   Read More

IP Explained: Why patents are so critical to biopharmaceutical innovation

By Tom Wilbur  |    April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...   Read More

New report shows nearly 20 innovative medicines in development for sickle cell disease

By Andrew Powaleny  |    April 2, 2019
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have...   Read More

New report: Using march-in authority would jeopardize U.S. innovation

By Tom Wilbur  |    March 19, 2019
In 1980, Congress passed the Small Business Patent Procedures Act, better known as the Bayh-Dole Act, which created a uniform framework for transferring government-funded research into useful...   Read More

In survey, PhRMA member companies highlight impact of IPI on R&D

By Katie Verb  |    February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....   Read More

Report: Corporate venture capital is catalyzing groundbreaking biomedical innovation in the United States

By Anne McDonald Pritchett, PhD  |    October 10, 2018
Venture capital is increasingly becoming the growing force for financing biotech and other startups, fueling medical advances in the U.S.  A new report released today from TEConomy, examines the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates